PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18022863-1 2007 Treatment of tumor-bearing mice with mouse (m)TNF-alpha, targeted to tumor vasculature by the anti-ED-B fibronectin domain antibody L19(scFv) and combined with melphalan, induces a therapeutic immune response. Melphalan 160-169 tumor necrosis factor Mus musculus 46-55 17330231-1 2007 Tumor necrosis factor (TNF) causes regression of advanced cancers when used in isolation perfusion with melphalan; evidence suggests these effects are mediated via selective yet uncharacterized actions on tumor neovasculature. Melphalan 104-113 tumor necrosis factor Mus musculus 23-26 28969419-7 2017 Moreover, in vivo antitumor efficacy was further significantly increased by combination treatment with the chemotherapeutic drug, melphalan, suggesting a synergistic effect attributable to enhanced drug uptake into the tumor as a result of TNFalpha-mediated enhanced vascular permeability. Melphalan 130-139 tumor necrosis factor Mus musculus 240-248 16397040-1 2006 PURPOSE: Subnanogram doses of NGR-tumor necrosis factor (TNF), a TNF-alpha derivative able to target tumor neovessels, can enhance the antitumor activity of doxorubicin and melphalan in murine models. Melphalan 173-182 tumor necrosis factor Mus musculus 30-55 16397040-1 2006 PURPOSE: Subnanogram doses of NGR-tumor necrosis factor (TNF), a TNF-alpha derivative able to target tumor neovessels, can enhance the antitumor activity of doxorubicin and melphalan in murine models. Melphalan 173-182 tumor necrosis factor Mus musculus 57-60 16397040-1 2006 PURPOSE: Subnanogram doses of NGR-tumor necrosis factor (TNF), a TNF-alpha derivative able to target tumor neovessels, can enhance the antitumor activity of doxorubicin and melphalan in murine models. Melphalan 173-182 tumor necrosis factor Mus musculus 65-74 16148157-4 2005 Neutralization of TNF prevented melphalan-induced apoptosis and liver cells derived from mice genetically deficient in either TNFR 1 or 2, but not from lpr mice lacking a functional CD95 receptor, were completely resistant. Melphalan 32-41 tumor necrosis factor Mus musculus 18-21 16148157-6 2005 Melphalan increased membrane-bound but not secreted TNF in Kupffer cells and inhibited recombinant TNF-alpha converting enzyme in vitro. Melphalan 0-9 tumor necrosis factor Mus musculus 52-55 16148157-6 2005 Melphalan increased membrane-bound but not secreted TNF in Kupffer cells and inhibited recombinant TNF-alpha converting enzyme in vitro. Melphalan 0-9 tumor necrosis factor Mus musculus 99-102 16148157-8 2005 In conclusion, this study shows that melphalan elicits membrane TNF on Kupffer cells due to inhibition of TNF processing and thereby initiates apoptosis of hepatocytes via obligatory activation of both TNFRs. Melphalan 37-46 tumor necrosis factor Mus musculus 64-67 16148157-8 2005 In conclusion, this study shows that melphalan elicits membrane TNF on Kupffer cells due to inhibition of TNF processing and thereby initiates apoptosis of hepatocytes via obligatory activation of both TNFRs. Melphalan 37-46 tumor necrosis factor Mus musculus 106-109 11673494-0 2001 Melphalan-induced expression of IFN-beta in MOPC-315 tumor-bearing mice and its importance for the up-regulation of TNF-alpha expression. Melphalan 0-9 tumor necrosis factor Mus musculus 116-125 11673494-1 2001 We have previously shown that administration of a low-dose of melphalan (L-phenylalanine mustard; L-PAM) to mice bearing a large s.c. MOPC-315 tumor leads to up-regulation of TNF-alpha expression, which is first evident at the mRNA level at 24 h after the chemotherapy. Melphalan 62-71 tumor necrosis factor Mus musculus 175-184 10452985-3 1999 Here, we show that NE inhibits the production of TNF-alpha protein and mRNA by l -PAM TuB spleen cells stimulated in vitro with mitomycin C-treated tumor cells. Melphalan 79-85 tumor necrosis factor Mus musculus 49-58 9225006-5 1997 Finally, TNF and GM-CSF may cooperate in enhancing the in vivo generation of CTL activity in MOPC-315 tumor bearers because low-dose melphalan (L-phenylalanine mustard) therapy, which was previously shown to lead to the rapid up-regulation of TNF production at the tumor site and the subsequent TNF-dependent in vivo acquisition of potent CTL activity, is shown here to lead to the rapid up-regulation of GM-CSF production at the tumor site. Melphalan 133-142 tumor necrosis factor Mus musculus 9-12 8635194-1 1995 We have previously shown the importance of endogenous tumor necrosis factor (TNF) production for the curative effectiveness of low-dose melphalan (L-phenylalanine mustard) for mice bearing a large MOPC-315 tumor. Melphalan 136-145 tumor necrosis factor Mus musculus 54-75 8635194-1 1995 We have previously shown the importance of endogenous tumor necrosis factor (TNF) production for the curative effectiveness of low-dose melphalan (L-phenylalanine mustard) for mice bearing a large MOPC-315 tumor. Melphalan 136-145 tumor necrosis factor Mus musculus 77-80 8635194-2 1995 In the current study we demonstrate that low-dose melphalan is actually associated with enhanced expression of mRNA for TNF alpha in the s.c. tumor nodule. Melphalan 50-59 tumor necrosis factor Mus musculus 120-129 8635194-5 1995 Moreover, neutralizing anti-IFN gamma mAb, like neutralizing anti-TNF mAb but not neutralizing anti-IL-12 mAb, reduced the curative effectiveness of low-dose melphalan for MOPC-315 tumor bearers. Melphalan 158-167 tumor necrosis factor Mus musculus 66-69 8635194-8 1995 Taken together, our studies illustrate that low-dose melphalan therapy of MOPC-315 tumor bearers is associated with the rapid elevation in the expression of mRNA for IFN gamma and TNF, two cytokines which are important for the curative effectiveness of low-dose melphalan, and which mediate their antitumor effect, in part, through distinct mechanisms. Melphalan 53-62 tumor necrosis factor Mus musculus 180-183 7706732-0 1995 Importance of TNF production for the curative effectiveness of low dose melphalan therapy for mice bearing a large MOPC-315 tumor. Melphalan 72-81 tumor necrosis factor Mus musculus 14-17 7882302-5 1995 Non-cytotoxic doses of TNF had a super-additive interaction with L-PAM/heat. Melphalan 65-70 tumor necrosis factor Mus musculus 23-26 7882302-6 1995 Conversely, non-cytotoxic doses of L-PAM had super-additive interactions with TNF followed by hyperthermia. Melphalan 35-40 tumor necrosis factor Mus musculus 78-81